奥沙利铂联合卡培他滨一线治疗晚期肝内胆管癌的临床观察  

Oxaliplatin combined with capecitabine as the first-line chemotherapy for patients with advanced intrahepatic cholangiocarcinoma

作　　者：魏丽[1] 董敏[1] 吴祥元[1] 林曲[1] 李星[1] 

机构地区：[1]中山大学附属第三医院肿瘤内科,广州市510630

出　　处：《实用医学杂志》2011年第20期3755-3757,共3页The Journal of Practical Medicine

摘　　要：目的:探讨奥沙利铂联合卡培他滨一线治疗晚期肝内胆管细胞癌的疗效及安全性。方法:16例无法手术的晚期肝内胆管细胞癌患者接受以下化疗,奥沙利铂130mg/m2,d1;卡培他滨2000mg/m2,d1～14,每21天为1个周期(XELOX方案)。最多接受6个周期的化疗。结果:16例患者中CR0例,PR2例(12.5%),SD5例(31.2%),PD9例(56.2%),临床获益率43.7%,中位TTP2.1个月,中位生存时间7个月。主要毒副作用有骨髓抑制、外周神经毒性、消化道反应、手足综合征,多为1～2度,无治疗相关性死亡。结论:XELOX方案治疗晚期肝内胆管细胞癌有一定近期疗效,耐受性好。Objective To investigate the efficacy and safety of oxaliplatin combined with capecitabine as the first-line chemotherapy for advanced intrahepatic cholangiocarcinoma （ICC）. Methods Sixteen patients with advanced ICC received oxaliplatin 130 mg/m^2 at day i and capecitabine 2 000 mg/m^2 at days 1-14 （XELOX regimen）. The regimen was repeated every 21 days. A maximum of 6 treatment cycles were given. Results Of the 16 patients, there was no case of complete response, 2 of partial responses （12.5%）, 5 stable diseases （31.2%）, 9 progressions （56.2%）. At a mean follow-up of 7.3 months, the median time to progression and median time of survival were 2.1 months and 7 months respectively. The most common adverse events, mostly one or two degree, were myelosupression, peripheral neuropathy, diarrhea, nausea/vomitting, and hand/foot syndrome. No treatment- related death was recorded. Conclusions XELOX is an effective and well-tolerated first-line chemotherapy regimen for advanced ICC.

关 键 词：胆管肿瘤 奥沙利铂 卡培他滨 化学疗法 

分 类 号：R735.8[医药卫生—肿瘤]